NodThera to Participate in Cantor Global Healthcare Conference

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NodThera, a leading clinical-stage company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiovascular and neurologic diseases, today announced participation in the Cantor Global Healthcare Conference being held September 9-11, 2026, in New York, NY.

Members of the NodThera management team will be available to participate in one-on-one meetings on September 10, 2026.

About NodThera

NodThera is a leading clinical-stage company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiovascular and neurologic diseases driven by the NLRP3/IL-1 inflammation pathway. The Company’s lead program, ruvonoflast (f/k/a NT-0796), recently completed the Phase 2 RESOLVE-1 study with topline data expected in Q3 of 2026, and expects to report results from its ongoing Phase 2 RESOLVE-2 trial in Q4 2026. The Company expects to commence a Phase 3 registrational study of ruvonoflast in H1 of 2027. The Company is also advancing trabzanoflast (f/k/a NT-0150) for treatment of neurologic diseases and expects to communicate Phase 1 topline results in Q4 of 2026.

NodThera is backed by top-tier investors including Novo Holdings, Blue Owl Capital, F-Prime Capital, 5AM Ventures, Sofinnova Partners, Epidarex Capital, and Sanofi Ventures.

NodThera is headquartered in Boston, Massachusetts, with an R&D base in the UK.

Learn more at www.nodthera.com or follow the Company on LinkedIn.

Investors and Media
Argot Partners
[email protected]

You May Also Be Interested In

• Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
• Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
• Netskope Announces Strong Second Quarter Fiscal 2027 Financial Results